超声内镜引导胃肠造口术（EUS-GE）是一种治疗胃出口梗阻（GOO）的微创技术。 EUS 引导的球囊闭塞胃空肠造口旁路术 (EPASS) 旨在改善 EUS-GE 中的支架部署并最大程度地减少迁移。在这项研究中，我们评估了 EPASS 的长期结果。我们回顾性分析了 37 名接受过 EPASS 治疗的有症状、非难治性 GOO 患者（平均年龄 71 岁；21 名男性）。EPASS 取得了 94.6 % (35/37) 的技术成功率成功率包括 2 例支架误置。平均手术时间为 27.3 分钟，其中双球囊管插入时间为 10.4 分钟。 EPASS 后 7 天和 28 天，初始 GOO 分数分别从 0.43 提高到 2.14 和 2.60。临床成功率为89.2%。包括发烧和腹痛在内的不良事件发生率为16.2%。 EPASS 后的平均总生存期为 193.5 天，无支架闭塞或移位（100% 通畅）。EPASS 证明了 EUS-GE 的安全性和可靠性，为有症状的恶性 GOO 治疗提供了可行的选择。版权所有 © 2024 美国胃肠病学会内窥镜检查。由爱思唯尔公司出版。保留所有权利。

Endoscopic ultrasonography-guided gastroenterostomy (EUS-GE) is a minimally invasive technique for gastric outlet obstruction (GOO). EUS-guided balloon-occluded gastrojejunostomy bypass (EPASS) aims to improve stent deployment and minimize migration in EUS-GE. In this study, we evaluated the long-term outcomes of EPASS.We retrospectively analyzed 37 patients (mean age 71; 21 males) with symptomatic, non-refractory GOO who had undergone EPASS.EPASS achieved a 94.6 % (35/37) technical success rate including 2 cases of stent mis-deployment. The mean procedure time was 27.3 min, with a double-balloon tube insertion time of 10.4 min. Initial GOO scores improved from 0.43 to 2.14 and 2.60 at 7 and 28 days post-EPASS, respectively. The clinical success rate was 89.2%. The rate of adverse events, including fever and abdominal pain, was 16.2%. The mean overall survival post-EPASS was 193.5 days, with no stent occlusion or migration (100% patency).EPASS demonstrates safety and reliability in EUS-GE, offering a viable option for symptomatic malignant GOO treatment.Copyright © 2024 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.